In the last few years, life sciences innovation has jumped by leaps and bounds. Many of the emerging autologous, patient-specific therapies being released are accomplishing things the general public never thought would be possible. These autologous treatments are...
Emerson’s Bruce Greenwald, Christian Berg, and David Gray collaborated to present “Solutions for Advanced Therapeutics” at the Emerson Exchange 2025 Conference.
The life sciences industry is changing rapidly. Where once companies were focused on developing blockbuster treatments and manufacturing them as quickly and safely as possible, today, personalized medicine has changed that landscape. Now life sciences companies are...
Emerson offers an integrated Spectral PAT solution for DeltaV, allowing manufacturers to pursue closed-loop control (and real-time quality assessments) using in-line spectroscopic instruments.
On Monday at the Emerson Exchange Users’ Conference, Emerson’s Michalle Adkins and AbbVie’s Jeff Ziolkowski moderated a panel with Fujifilm’s Soren Skerris, Takeda’s Dr. Nina Schwalb, Eli Lilly’s James Weber, and Emerson’s Christian Berg. The experts shared the...
Christian Berg describes some solutions and technologies which facilitate the pursuit of the adaptive plant for manufacturers in the Life Sciences industry, as defined by the BioPhorum Digital Plant Maturity Model.
In a Pharma Focus Asia webinar, Pursuing the Adaptive Plant to Enable Personalized Healthcare, Emerson’s Christian Berg provides a broader perspective of personalized healthcare and its challenges for the Life Sciences industry.
The BioPhorum Operations Group (BPOG) established a digital plant maturity model (DPMM) for biopharmaceutical manufacturing to define stages of factory evolution “from simple paper-based plants through to the fully automated and integrated ‘adaptive plant’ of the future.” The model gives organizations a common tool for industry comparison and measurement of progress. It also provides a platform to facilitate collaboration within the life sciences industry and its technology providers.
Emerson’s Christian Berg presented Are We There Yet? Tackling Manufacturing Challenges with the Digital Plant at the Pharma Manufacturing World Summit in Boston.
Initiating Good Manufacturing Practices (GMP) production operations, whether as part of facility start-up, product changeover, or following a shutdown, requires complex coordination of both logical and physical process controls. Inefficient configuration and qualification practices for automation and information management systems can lead to both start-up delays and productivity losses.
Flow is the foundation of world class production processes. Impediments to flow result in waste (transportation, inventory, motion, waiting, over-processing, over-production, defects). Unfortunately, digital solutions are often leveraged to address observed wastes in production processes without first addressing foundational problems.
Our Global Community
Emerson Exchange 365
This blog features expert perspectives from Emerson's automation professionals on industry trends, technologies, and best practices. The information shared here is intended to inform and educate our global community of users and partners.